|
||||
|
|
|
|||||||||
| Friday, November 26, 2004 |
| 16.00 – 17.00 | Board Meeting of the Alp-Danube-Adria Society for STDs and Skin Infections | |
| 18.00 | Welcoming
addresses A. Stary H. J. Rauch J. Söltz-Szöts J. Lipozencic A. Kansky |
|
| 18.30 | Keynote
lecture: Chair: J. Lipozencic, A. Stary |
|
| 1 | G. Stingl,
Vienna: Immunostimulation via the skin – a new approach for the treatment of inflammatory and neoplastic skin diseases |
|
| 19.00 | Welcome reception at the Parkhotel Schönbrunn |
| Saturday, November 27, 2004 |
| 8.30 – 9.00 | Case reports Chair: C. Heller-Vitouch, V. Varkonyi |
|
| 2 | V. Várkonyi,
T. Somogyi , G. Veres, A. Horváth, Budapest: Diagnostic problems with syphilis: recent cases |
|
| 3 | T. Gregurek-Novak,
Zagreb: Do we always think of syphilis? |
|
| 4 | E. Messeritsch,
A. Geusau, Vienna: Ocular manifestion in secondary syphilis |
|
| 5 | K. Chudomirova,
V. Dosheva, S. Popov, V. Garov, Plovdiv: Neurosyphilis – a case report |
|
| 6 | L. Richter,
I. Heinrich, K. Rappersberger, Vienna: Bowen’s disease of the vulva – successful treatment with Imiquimod |
|
| 7 | C. M. Rudolph,
R. R. Müllegger, H. Kerl, G. Ginter-Hanselmayer, Graz: Systemic antifungal treatment of disseminated tinea corporis in late pregnancy. Report of two cases |
|
| 9.00 – 10.45 | Session I Epidemiology of STIs in an expanding Europe Chair: A. Horvath, S. Mayerhofer |
|
| 8 | Plenary lecture K. Fenton, London: Epidemiology of STIs in an expanding Europe |
|
| 9 | A. Horvath,
Budapest: Sociological relation of syphilis epidemic in Hungary |
|
| 10 | S. Mayerhofer,
E. Vinzelj, M. Emri-Gasperlmair, Vienna: Classical venereal diseases at the Viennese public health department |
|
| 11 | I. Kuklova,
V. Kastankova, R. Pankova, H. Zakoucka, M. Drazdakova, R. Tryzna, J. Jedlicka,
H. Malinova, R. Mak, Prague: Outreach programme for female sex workers in Prague – the first results |
|
| 12 | I. Klavs, L.
C. Rodrigues, K. Wellings, D. Ke¡se, R. Hayes, Ljubljana/London: Prevalence of genital Chlamydia trachomatis infection in the general population of Slovenia |
|
| 13 | B. Götz,
E. Schuh, B. Stary, G. Gittler, A. Stary, Vienna: Chlamydia screening in university students in Vienna |
|
| 14 | M. Potocnik,
A. Godic, I. Bartenjev, Ljubljana: STIs in Slovenia, what happened in the last decade? |
|
| 10.45 – 11.15 | Coffee Break | |
| 11.15 – 12.20 | Session II Viral STIs Chair: A. Kansky, G. Stingl |
|
| 15 | Plenary lecture: J. Paavonen, Helsinki: HPV Vaccination: The beginning of the end of cervical cancer |
|
| 16 | B. Hönlinger,
N. Romani, C.-P. Czerny, H. Huemer, R. Höpfl, Innsbruck/Göttingen: Re-emerging animal orthopoxvirus infections in the light of potential bioterrorism |
|
| 17 | S. Ljubojevic,
N. Ljubojevic, J. Lipozencic, M. Skerlev, L. Zele-Starcevic, Zagreb: Peniscopy in diagnostic procedure of subclinical human papilloma virus infection |
|
| 18 | J. Pec, I.
Chromej, J. Kliment, S. Urbancek, Martin: Squamous cell carcinoma of the penis and STD. Situation in the central region of the Slovak Republic |
|
| 12.30 – 13.45 | Lunch Symposium
(sponsored by Digene) HPV-Diagnosis Chair: M. Skerlev, J. Söltz-Szöts |
|
| 19 | H. Ikenberg,
Bad Münder: HPV testing as a routine method in the prevention of cervical cancer |
|
| 20 | J. Tarra, K.
Straka, A. Stary, Vienna: HPV genotyping in STI patients |
|
| 21 | C. Heller-Vitouch,
J. Söltz-Szöts, Vienna: Interpretation and consequences of HPV diagnosis |
|
| 22 | M. Skerlev,
Zagreb: Problem warts and problem patients in the male HPV-world |
|
| 14.00 – 15.30 | Session III HIV Chair: K. Nagy, E. Tschachler |
|
| 23 | Plenary Lecture: M. Youle, London: Update on AIDS and HIV |
|
| 24 | A. Rieger,
Vienna: The acute retroviral syndrome |
|
| 25 | E. Tschachler,
Vienna: New insights into Kaposi’s sarcoma pathogenesis |
|
| 26 | K. Nagy, Budapest: Characteristics of HIV/AIDS epidemic in Hungary |
|
| 15.30 – 16.00 | Coffee Break | |
| 16.00 – 17.00 | Session IV Tropical Infections of the Skin Chair: G. Klein, J. Lipozencic |
|
| 27 | Plenary
Lecture: B. Naafs, Munnekeburen: Skin infections in the tropics |
|
| 28 | R. Moser, Eisenstadt: Cutaneous leishmaniasis |
|
| 29 | G. Klein, Linz: Regional dermatological training centre in Tanzania: experiences and challenge |
|
| 20.00 | Social Dinner
at the “Lusthaus” (departure of buses from the Parkhotel Schönbrunn at 19.15) |
| Sunday, November 28, 2004 |
| 8.30 – 10.30 | Session V Bacterial STIs – Diagnosis and Treatment Chair: M. Potocnik, A. Stary |
|
| 30 | K. Nagy, B.
Kemeby, V. Varkonyi, A. Horvath, Budapest: Molecular screening of syphilis by PCR |
|
| 31 | G. Veres, V.
Várkonyi, S. Illniczky, I. Horváth, K. Nagy, A. Horváth,
Budapest: Early neurosyphilis. Symptoms and management |
|
| 32 | S. Wöhrl,
A. Geusau, Vienna: Neurosyphilis is unlikely in patients with late latent syphilis and a negative blood VDRL |
|
| 33 | Plenary
Lecture A. Põder, Tartu: Impact of IUSTI on STI surveillance in Estonia |
|
| 34 | P. Komericki,
M. Akkilic, M. Haller, L. Teodorowicz, W. Aberer, A. Stary, Graz/Vienna: Increasing failure of gonococcal culture on a selective medium |
|
| 35 | A. Zore, M.
Petrovec, D. Ke¡se, E. Ru¡zi´c-Sablji´c, M. Poto¡cnik,
M. Gubina, Ljubljana: Ciprofloxacin resistant strains of Neisseria gonorrhoeae in Slovenia from 2001 to 2004 |
|
| 36 | M. Haller,
A. Bilina, P. Fuhrmann, C. Heller-Vitouch, A. Kuchinka-Koch, L. Teodorowicz, A. Stary, Vienna: Neisseria gonorrhoeae: resistance profile from 1999 to 2003 |
|
| A. Stary, Vienna: Presentation of the Austrian Guidelines for the Treatment of STIs 2004 |
||
| 10.30 – 11.00 | Coffee Break | |
| 11.00 – 12.00 | Session VI Treatment issues of Fungal Infections Chair: G. Ginter-Hanselmayer, G. Trevisan |
|
| 37 | W. Weger, G.
Ginter-Hanselmayer, S. Pitzl, A. Paulitsch, P. Komericki, M. Akkilic, W. Buzina, Graz: Vaginal yeast isolates – do we need species identification? |
|
| 38 | A. Uthman,
M. Dockal, J. Söltz-Szöts, E. Tschachler, Vienna: Fluconazole upregulates sconC expression and inhibits sulphur metabolism in Microsporum canis |
|
| 39 | F. Kokelj,
G. Trevisan, Triest: Side effects and drug interactions of modern oral antimycotic drugs |
|
| 12.00 – 12.15 | Closing Remarks |
 |
 |
||||||||||||||||
|
|
 |